Chronic Cladribine Administration Increases Amyloid Beta Peptide Generation and Plaque Burden in Mice

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Hayes, Crystal D ^a   Dey, Debleena ^a   Palavicini, Juan Pablo ^a   Wang, Hongjie ^a   Araki, Wataru ^b   Lakshmana, Madepalli K ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN 751; ANTIBODY; BIOTIN; BIOTIN ANTIBODY; CLADRIBINE; CYCLOHEXIMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CELL SURFACE; CHO CELL; CHRONIC DRUG ADMINISTRATION; CIS TRANS ISOMERISM; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MAZE TEST; MEMORY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; REWARD; TASK PERFORMANCE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CLADRIBINE; CRICETINAE; CRICETULUS; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE AGENTS; MAZE LEARNING; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PEPTIDYLPROLYL ISOMERASE; PLAQUE, AMYLOID;

ANIMALIA; MUS;

EID: 84867034450     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045841     Document Type: Article

References (54)

1. Beutler E, (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952-956.
2. Sipe JC, (2005) Cladribine for multiple sclerosis: Review and current status. Expert Review of Neurotherapeutics 5: 721-727.
3. Carson DA, Wasson DB, Taetle R, Yu A, (1983) Specific toxicity of 2 chlorodeoxyadenosine toward resting and proliferating human lymphocytes, Blood. 62: 737-743.
4. Carson DA, Kaye J, Seegmiller JE, (1977) Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase. Proc. Natl. Acad. Sci. U. S. A. 74: 5677-5681.
5. Liliemark J, (1997) The clinical pharmacokinetics of cladribine, Clin. Pharmacokinet. 32: 120-131.
6. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, et al. (1993) Relationship of deoxycytidine kinase and cytoplasmic 50- nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine, Blood. 81: 597-601.
7. Available: http://biogps.gnf.org.Accessed 2012 May.
8. Salvat C, Curchod M-L, Guedj E (2009) Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis (Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Dusseldorf, Germany, 9Y12, [Poster P280]. Poster presented at ECTRIMS 2009.
9. Hartman WR, Hentosh P, (2004) The antileukemia drug 2-chloro-2′-deoxyadenosine: an intrinsic transcriptional antagonist. Mol Pharmacol 65: 227-234.
10. Lotfi K, Juliusson G, Albertioni F, (2003) Pharmacological basis for cladribine resistance. Leuk Lymphoma 44: 1705-1712.
11. Lindemalm S, Liliemark J, Juliusson G, Larsson R, Albertioni F, (2004) Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 210: 171-177.
12. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA, (1985) Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes, J. Clin. Invest. 75: 377-383.
13. Hentosh P, Peffley DM, (2010) The cladribine conundrum: deciphering the drug's mechanism of action. Expert Opin. Drug Metab. Toxicol. 6: 75-81.
14. Ogura M, Morishima Y, Kobayashi Y, Ulke N, Sugai S, et al. (2004) Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int. J. Hematol. 80: 267-277.
15. Saven A, Piro LD, (1994) 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann. Intern. Med. 120: 784-791.
16. Robak T, Blonski JZ, Kasznicki M, Konopka L, Ceglarek B, et al. (2000) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia- updated results of the multicenter study of 378 patients. Br J Haematol 108: 357-368.
17. Rummel MJ, Chow KU, Jager E, Hossfeld DK, Bergmann L, et al. (1999) Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol 10: 115-117.
18. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, et al. (2006) Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer 107: 2817-2825.
19. Schirmer M, Mur E, Pfeiffer KP, Thaler J, Konwalinka G, (1997) The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand. J. Rheumatol. 26: 376-379.
20. Davis JC Jr, Austin III H, Boumpas D, Fleisher TA, Yarboro C, et al. (1988) A pilot study of 2-chloro-2-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum. 41: 335-343.
21. Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, et al. (2011) Evaluation of cladribine treatment in refractory celiac disease type II. World J. Gastroenterol. 17: 506-513.
22. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E, (1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 111: 35-44.
23. Rice GP, Filippi M, Comi G, (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54: 1145-1155.
24. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344: 9-13.
25. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckman P, et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416-426.
26. Gasperini C, Ruggieri S, (2011) Emerging oral drugs for relapsing-remitting multiple sclerosis. Expert Opin Emerg. Drugs 16: 697-712.
27. Khachanova NV, (2011) A plan for risk management in the treatment of multiple sclerosis with movectro (cladribine tablets). Zh Nevrol Psikihiatr Im S S Korsakova 111: 99-104.
28. Duddy M, Haghikia A, Cocco E, Eggers C, Drulovic J, et al. (2011) Managing MS in a changing treatment landscape. J. Neurol. 258: 728-39.
29. Gold R, (2011) Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 25: 37-52.
30. European Union, European Medicines Agency (online). Available: www.ema.europa.eu2010. Accessed 2012 Jul 11.
31. United States Food and Drug Administration (online). Available: www.fda.gov2011. Accessed 2012 Jul 11.
32. Asher A, (2011) Cognitive dysfunction among cancer survivors. Am. J. Phys. Med. Rehabil. 90: S16-26.
33. Zachariae R, Mehlsen MY, (2011) Is chemotherapy associated with cognitive impairment? Nat. Rev. Urol. 8: 182-183.
34. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, (2011) Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J. Pain Sympt. Manag. 41: 126-139.
35. Liliemark J, (1997) The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 32: 120-31.
36. Cheson BD, Vena DA, Foss FM, Sorensen JM, (1994) Neurotoxicity of purine analogs: a review. J. Clin. Oncol. 12: 2216-28.
37. Hartung HP, Aktas O, Kieseier B, Giancarlo Corni GC, (2010) Development of oral cladribine for the treatment of multiple sclerosis. J Neurol 257: 163-170.
38. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, et al. (1994) Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84: 3429-3434.
39. Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, et al. (1993) 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol. 11: 671-678.
40. Development Therapeutics Program [homepage on the Internet]. NCI/NIH. Available: http://dtp.cancer.gov. Accessed 2012 May 15.
41. Lakshmana MK, Yoon IS, Chen E, Park SA, Bianchi E, et al. (2009) Novel role of RanBP9 in BACE1 processing of APP and amyloid beta peptide generation. J. Biol. Chem. 284: 1863-1872.
42. Lakshmana MK, Chung JY, Wickramarachchi S, Tak E, Bianchi E, et al. (2009) A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid beta peptide generation. FASEB J. 24: 119-127.
43. Deacon RM, Rawlins JN, (2006) T-maze alternation in the rodent. Nat Protoc. 1: 7-12.
44. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC, (2005) Alzheimer's disease and cancer. Neurology 64: 895-898.
45. Koo EH, Squazzo SL, (1994) J. Biol. Chem. 269: 17386-17389.
46. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, et al. (1999) Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J. Biol. Chem. 274: 18851-18856.
47. Available: http://biogps.gnf.org/.Accessed 2012 Jul 11.
48. Netzer WJ, Dou F, Cai D, Veach D, Jean S, et al. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 100: 12444-12449.
49. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 335: 1503-1506.
50. Djaldetti R, Hart J, Alexandrova S, Cohen S, Beilin B, et al. (1996) Effect of high doses of 2-CdA on Schwann cells of mouse peripheral nerve. J Submicrosc Cytol Pathol. 28: 319-23.
51. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, et al. (2006) The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature. 440: 528-34.
52. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP, (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated Tau protein. Nature 399: 784-788.
53. Sultana R, Boyd-Kimball D, Poon HF, (2006) Oxidative modification and down-regulation of PIN 1 in Alzheimer's disease hippocampus. A redox proteomix analysis. Neurobiol. Aging 27: 918-925.
54. Myers JS, (2012) Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol. Nurs. Forum 39: E31-E40.